Asa Schott

Company: Idogen AB

Job title: Chief Scientific Officer

Seminars:

A Novel Tolerogenic Dendritic Cell Platform with the Potential to Present the Antigen FVIII to Induce Tolerance Against FVIII in Haemophilia A Patients 11:30 am

Presentation of a novel and patented platform for generation of tolerogenic DCs Hear how the tolerogenic DCs have a potential to induce regulatory T and to reduce antigen-specific T cell responses Learn how tolerogenic DCs loaded with FVIII can be used to treat haemophilia A patients who developed inhibitorsRead more

day: Day Two